TORONTO, Aug. 29, 2013 /CNW/ - UCB Canada Inc. announced today that
NEUPRO® (rotigotine) is now available in Canada for the treatment of
The availability of NEUPRO® in Canada follows Health Canada's approval
in March, making it the first new treatment for Parkinson's disease
approved in Canada in five years. NEUPRO® is the first and only
non-ergolinic dopamine agonist available in a patch, and provides
24-hour delivery of rotigotine through the skin into the blood stream.
NEUPRO® has demonstrated efficacy in managing motor symptoms associated
with Parkinson's disease.
"As a company committed to bringing meaningful medications to Canadians
for serious medical conditions, such as Parkinson's disease, we are
very pleased that NEUPRO® is a new option available by prescription
from physicians," says Dr. Gordana Atanackovic, Director, Medical
Affairs , UCB Canada Inc. "Based on clinical evidence and patient
experience from numerous countries, we are confident that NEUPRO® can
improve quality of life for many Canadians with Parkinson's disease
which is very important for people struggling with its disruptive
symptoms, such as on-off periods."
About Parkinson's disease
Parkinson's disease (PD) is a chronic, degenerative neurological disease
which affects approximately 100,000 Canadians. PD develops with the
loss of nerve cells in the brain that produce a chemical called
dopamine. The symptoms of PD can have an impact on many dimensions of
patients' lives. As dopamine levels fall, movement (motor)
symptomstremors (uncontrollable shaking), rigidity (stiffness or
muscle tensing) and bradykinesia (slowness and loss of spontaneous
movement) can progress, along with the underlying symptoms of PD,
which are less well recognized and may be under-treated.
About UCB Canada Inc.
Inspired by patients and driven by science, UCB Canada Inc. is a
biopharmaceutical company focused on the discovery and development of
innovative medicines and solutions to transform the lives of people
living with severe auto-immune and central nervous system diseases. For
more information, please consultwww.ucb.com/worldwide/canada.
SOURCE UCB Canada Inc.